0001144204-19-033900 Sample Contracts
Acura Pharmaceuticals Licenses LIMITx™ LTX-03 Agreement Provides For Completion of Development and Commercialization Transaction Valued at up to $21.3 Million, not including RoyaltiesLicense, Development and Commercialization Agreement • July 5th, 2019 • Acura Pharmaceuticals, Inc • Pharmaceutical preparations
PALATINE, IL, July 2, 2019: Acura Pharmaceuticals, Inc. (OTC Pink: ACUR) today announced a License, Development and Commercialization Agreement (the "Agreement") with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”), a special purpose company representing a consortium of investors that will finance Acura’s operations and completion of development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™ technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. AD Pharma retains commercialization rights from which Acura will receive royalties and potential sales related milestones.
